Piper Sandler analyst Edward Tenthoff reiterates Fate Therapeutics (NASDAQ:FATE) with a Overweigh

Wells Fargo analyst Yanan Zhu maintains Fate Therapeutics (NASDAQ:FATE) with a Equal-Weight and r

Wedbush analyst Martin Fan reiterates Fate Therapeutics (NASDAQ:FATE) with a Outperform and main

First patient dosed in an outpatient setting, discharged the same day; multiple patients in the proc

First patient dosed in an outpatient setting, discharged the same day; multiple patients in the proc

Fate Therapeutics (FATE) came out with a quarterly loss of $0.25 per share versus the Zacks Consensu

Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.25) per share which beat the analys

First lupus nephritis patient dosed in RECLAIM-LN, a Phase 2 potentially registrational trial utiliz

Sen. Cynthia Lummis, R-Wyo., discusses the expected CLARITY Act vote, the budget agenda before reces

SAN DIEGO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stag

US stock futures mostly higher, Nasdaq up by 100 points. Phoenix Education falls after cutting sales

Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bring

First-of-Kind, Dual-CAR T cell Targeting CD19 and CD38 for Comprehensive Elimination of Complex, Mul

Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bring

SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stag

SAN DIEGO, July 01, 2026 (GLOBE NEWSWIRE) --  Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-sta

Fate Therapeutics is a bet on their off-the-shelf cell therapies, which are now mostly centered on F

SAN DIEGO, June 15, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stag

HC Wainwright & Co. analyst Robert Burns reiterates Fate Therapeutics (NASDAQ:FATE) with a Bu

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to brin

FT819 off-the-shelf CAR T-cell therapy product candidate continues to broaden patient access with 21

SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stag

FT836 demonstrates meaningful reduction in target lesions without the use of conditioning chemothera

/PRNewswire/ -- USA News Group Market Commentary - Start with the number that makes everyone do a do

Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bring

SAN DIEGO, May 21, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage

Fate Therapeutics (FATE) came out with a quarterly loss of $0.26 per share versus the Zacks Consensu

Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.26) per share which beat the analys

RECLAIM – LN, a Phase 2 potentially registrational clinical trial of FT819 in patients with refracto

Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bring

Single dose treatment of FT819 without conditioning chemotherapy achieves lupus low disease activity

Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bring

Fate Therapeutics will present clinical and translational data from the systemic lupus erythematosus

HC Wainwright & Co. analyst Robert Burns maintains Fate Therapeutics (NASDAQ:FATE) with a Buy

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to brin

Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bring

Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.27) per share which missed the anal

FT819 continues to demonstrate meaningful decrease in disease and favorable safety profile with twel

Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.27) per share which beat the analys

HC Wainwright & Co. analyst Robert Burns upgrades Fate Therapeutics (NASDAQ:FATE) from Neutra

Wedbush analyst David Nierengarten upgrades Fate Therapeutics (NASDAQ:FATE) from Neutral to Outpe

As of a September 25, 2025 data cut-off-date, 10 patients with treatment-refractory, moderate-to-sev

Wells Fargo analyst Yanan Zhu maintains Fate Therapeutics (NASDAQ:FATE) with a Equal-Weight and l

Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.29) per share which beat the analys

All three patients treated with FT819 following fludarabine-free conditioning regimen for severe lup

Barclays analyst Peter Lawson maintains Fate Therapeutics (NASDAQ:FATE) with a Overweight and low